DiaCarta is a leading precision diagnostic company specializing in providing comprehensive one-stop-shop for cancer patient management solutions.
1
Early Detection/Screening
2
Diagnosis
3
Therapy Selection
4
Therapy Monitoring
Our offerings
Our proprietary XNA technology and isobDNA™ technology allow for sensitive, accurate, and cost-effective detection of genetic alterations using different genomic platforms, positioning us as a leader in the precision diagnostic industry.
Our suite of diagnostic products and services, including RadTox™, ColoScape™, and Oncuria®, along with our range of infectious disease tests, such as HPV tests and MonkeyPox tests, deliver superior clinical performance and economic value to healthcare providers and patients worldwide.
Global Expansion
Our team of world-class scientists, clinicians, and industry experts is dedicated to advancing precision medicine through continued investment in research and development, strategic partnerships, and global expansion.
ISO 13485 certified GMP manufacturing facility
Based in California, USA, with global subsidiaries in Europe and Asia
Innovative R&D lab
CAP-accredited CLIA lab
Affordable Excellence with Unmatched Sensitivity and Specificity
XNA Technology
Current genomics technology has improved a lot. We can now detect genetic/somatic mutations in tissue samples (biopsy) and even in body fluids (liquid biopsy). Still, it is tough to find rare genetic changes, especially those in early-stage cancer or residual cancer cells (MRD, or Molecular Residual Disease, monitoring).
XNA technology solves this problem by boosting sensitivity and specificity in traditional platforms like Sanger sequencing, qPCR, ddPCR, and NGS, without changing the existing protocol.
High-throughput and sensitive mutation detection and quantification capability without DNA sequencing
isobDNA™ Technology
Tools like qPCR and ddPCR are often used to quantify gene copy number and gene expression. But, to get accurate results, we first need to extract and purify the DNA or RNA from samples. The problem is, during the extraction, we will lose some DNA or RNA. This becomes a big concern when we only have a small amount of samples to start with.
isobDNA™ technology solves the problem because it does require the sample extraction process. Instead of amplifying the targets like PCR technology, isobDNA technology amplifies the signals. It’s just as sensitive as PCR but more accurate.
Florida Selects DiaCarta’s cfDNA Test (RadTox™) for Statewide Use to Detect Early Response of Cancer Treatment
DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly announced that Florida Health Department selected “using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance” through the Casey DeSantis Florida Cancer Innovation Fund. This fund supports deployment of the RadTox™ test throughout the State of Florida to be performed between Radiotherapy or Chemotherapy doses for real time detection of treatment response or resistance. The results will be as a real time predictor of imaging data.
DiaCarta Announces That the Oncuria® Bladder Cancer Tests Receive Medicare Coverage Effective January 1, 2024
DiaCarta proudly announced that the Oncuria® Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a Lab Developed Test (LDT), at its CAP-accredited and CLIA-certified laboratory, have received Medicare coverage effective January 1, 2024.
NGS test for colorectal cancer to guide targeted therapy
Colorectal cancer (CRC) can develop from germline genetic mutations inherited from family or somatic mutations developed later in life. Our Optiseq™ colorectal cancer NGS for mutation detection panel covers genes associated with both hereditary and somatic mutations...
Detection of ROS1, RET, and ALK fusions in non-small cell lung cancer
ROS1 (c-ros oncogene 1), RET (rearranged during transfection), and ALK (anaplastic lymphoma kinase) are receptors of tyrosine kinases that play important roles in cell growth and differentiation. ROS1, RET or ALK fusion is formed by chromosomal rearrangements that...